Objective: Primary aldosteronism (PA) is the most common secondary cause of hypertension. Patients with PA experience significant cardiovascular and other complications comPrimary aldosteronism (PA) is the most common secondary cause of hypertension. Patients with PA experience significant cardiovascular and other complications compared to patients with primary hypertension for the same degree of blood pressure control. Guidelines recommend screening all patients with resistant hypertension for PA.
OBJECTIVE: The objective of this study was to assess screening rate for PA among patients with apparent treatment resistant hypertension and to determine the rate of positive screening test result among the group screened.
METHODS: This is a retrospective chart review of electronic medical record data of all patients with hypertension and >18 years within a single health system in Minnesota from September 2018 - September 2020.
RESULTS: Out of 140,734 patients who were>18 years with a diagnosis of hypertension, 13.4% (18,908) fulfilled the criteria for apparent treatment resistant hypertension after excluding those with congestive heart failure. Only 4.2% (795) of patients with apparent treatment resistant hypertension had screening for PA in our cohort. Of the 795 patients who had screening for PA, 16.9% (134) had a positive screening test result.
CONCLUSION: The screening rate for PA among patients with resistant hypertension is low. Clinical and public health strategies directed at improving screening rate for PA are vital.
|Original language||English (US)|
|Number of pages||5|
|State||E-pub ahead of print - Nov 26 2021|
Bibliographical noteFunding Information:
We thank the informatics consulting service of the Clinical and Translational Science Institute of the University of Minnesota. The research reported in this publication was supported by National Institutes of Health grant P30 CA77598 using the Biostatistics Core shared resource of the Masonic Cancer Center, University of Minnesota , and by the National Center for Advancing Translational Sciences of the National Institutes of Health Award Number UL1TR002494. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
© 2021 AACE
- apparent treatment-resistant hypertension
- primary aldosteronism
- resistant hypertension
PubMed: MeSH publication types
- Journal Article